ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatology"

  • Abstract Number: 1599 • 2016 ACR/ARHP Annual Meeting

    Speed of Onset of Effect on Patient-Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program

    Peter C. Taylor1, Grace C. Wright2, Carol L. Gaich3, Amy M. DeLozier3, Stephanie de Bono3, Douglas E. Schlichting3, Terence Rooney3, Jiajun Liu3, Scott D. Beattie4 and Maxime Dougados5, 1NDORMS, University of Oxford, Oxford, United Kingdom, 2NYU Langone Medical Center, New York, NM, 3Eli Lilly and Company, Indianapolis, IN, 4Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 5Dept of Rheumatology, Cochin Hospital, Paris, France

    Background/Purpose: Baricitinib (bari), an oral Janus kinase (JAK) 1/JAK2 selective inhibitor, has demonstrated clinical efficacy with a satisfactory safety profile when administered once daily in…
  • Abstract Number: 2029 • 2016 ACR/ARHP Annual Meeting

    Risk of Knee Pain, Radiographic Osteoarthritis and Knee Arthroplasty in Retired Professional Footballers Compared to the General Population 

    Gwen Fernandes1,2,3, Sanjay M Parekh1,2, Jonathan P Moses1,2, Colin Fuller4, Brigitte Scammell1,2,3, Mark Batt1,2,3, Weiya Zhang1,2,3 and Michael Doherty1,2,3, 1Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 2Arthritis Research UK Centre for Sports, Exercise and Osteoarthritis, Nottingham, United Kingdom, 3Arthritis Research UK Pain Centre, Nottingham, United Kingdom, 4Colin Fuller Consultancy Ltd, Nottingham, United Kingdom

    Background/Purpose: To determine the prevalence of knee pain (KP),  radiographic knee osteoarthritis (RKOA) and total knee replacements (TKR) in ex-professional footballers compared to general population…
  • Abstract Number: 2584 • 2016 ACR/ARHP Annual Meeting

    Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated with Conventional Disease-Modifying Antirheumatic Drugs

    Jonathan Kay1, Joshua Rancourt2, John D. Bradley2, Vipin K. Arora2, Jinglin Zhong3, Christina Dickson2 and David Muram2, 1Rheumatology Center, Memorial Campus, UMass Memorial Medical Center, Worcester, MA, 2Eli Lilly and Company, Indianapolis, IN, 3Quintiles, Rockville, MD

    Background/Purpose:   Anemia in rheumatoid arthritis (RA) patients (pts) has a prevalence of 16%-64% depending on population and severity of disease1,2,3 and is more common…
  • Abstract Number: 3023 • 2016 ACR/ARHP Annual Meeting

    Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies

    Iain B. McInnes1, Joel Kremer2, Paul Emery3, Steven H. Zuckerman4, Giacomo Ruotolo4, Chadi Saifan4, Lei Chen4, Shayami Thanabalasundrum4, Sarah Witt4 and William Macias4, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain, 2The Center for Rheumatology, Albany Medical College, Albany, NY, 3University of Leeds, Midlothian, United Kingdom, 4Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: In patients with active RA an increase in lipid analytes has been observed after treatment with janus kinase inhibitors and other disease-modifying antirheumatic drugs.1…
  • Abstract Number: 3027 • 2016 ACR/ARHP Annual Meeting

    Herpes Zoster in Patients with Moderate to Severe Rheumatoid Arthritis Treated with Baricitinib

    Kevin L. Winthrop1, Stephen Lindsey2, Michael Weinblatt3, Tsutomu Takeuchi4, David Hyslop5, Maher Issa5, Lei Chen5, John Bradley5, Christina Dickson5 and Roy Fleischmann6, 1Oregon Health and Sciences University, Portland, OR, 2Ochsner Medical Center, Baton Rouge, LA, 3Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 4Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 5Eli Lilly and Company, Indianapolis, IN, 6Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Compared to the general population, RA patients (pts) have an increased risk of herpes zoster (HZ) due to their disease and various DMARD therapies…
  • Abstract Number: 1142 • 2016 ACR/ARHP Annual Meeting

    Impact of a Student Led Rheumatology Interest Group on Medical Student Interest in Rheumatology

    Timothy Brady1, Michael Sheppard2, N. Andrew LaCombe2, Sonia Silinsky Krupnikova2, Nora Taylor2, Pragya Singh1, Sean McNish1 and Victoria K. Shanmugam1, 1Division of Rheumatology, The George Washington University, Washington, DC, 2The George Washington University, Washington, DC

    Impact of a Student Led Rheumatology Interest Group on Medical Student Interest in Rheumatology Background/Purpose: Based on data from the 2005 Rheumatology Workforce Study the…
  • Abstract Number: 1584 • 2016 ACR/ARHP Annual Meeting

    Bari-00074565

    C. Steven Ernest II, Lisa O’Brien, David Radtke, Michael Heathman, Terence Rooney, William Macias and Xin Zhang, Eli Lilly and Company, Indianapolis, IN

    Background/Purpose:  Baricitinib is an oral selective inhibitor of Janus kinases 1/2 and has demonstrated dose-dependent efficacy in moderate-to-severe RA patients who were DMARD-naïve or with…
  • Abstract Number: 2717 • 2014 ACR/ARHP Annual Meeting

    Comparison of PROMIS® survey Between Scleroderma Patients in an Academic Center and Patient-Based Scleroderma Foundations

    Vivek Nagaraja1, Veronica Berrocal2, Kerri Connolly3, Ann Kennedy4, Daniela Seelmann5 and Dinesh Khanna1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, 3Scleroderma Foundation, Boston, MA, 4Federation of European Scleroderma Associations, Tournai, Belgium, 5Universidad de Los Andes, Santiago, Chile

    Background/Purpose The National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS®) roadmap initiative is a cooperative research program designed to develop, evaluate, and standardize…
  • Abstract Number: 1151 • 2014 ACR/ARHP Annual Meeting

    Barriers and Facilitators of a Career in Research Among Rheumatologists in the United States

    Alexis Ogdie1, Sheila Angeles-Han2, Una Makris3,  Amanda Nelson4, Ami Shah5, Yihui Jiang6, J. Michelle Kahlenberg7, Eyal Muscal8, Flavia V. Castelino9, Amit Golding10 and Alfred Kim11, 1Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, 2Pediatrics, Emory University School of Medicine, Atlanta, GA, 3Rheumatology, Dallas VA Medical Ctr, Dallas, TX, 45) Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 5Division of Rheumatology, John Hopkins University, Baltimore, MD, 6Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 7Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 8Rheumatology, Texas Children's Hospital, Houston, TX, 9Rheumatology, Massachusetts General Hospital, Boston, MA, 10Medicine/Rheumatology and Clinical Immunology, Baltimore VA and University of Maryland School of Medicine, Baltimore, MD, 11Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO

    Background/Purpose: Development of young rheumatology investigators is critical to the future of rheumatology.  Beyond funding, the specific barriers to maintaining a career in rheumatology research…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology